Keros Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	0.15	0	20.1	0	10	10
Gross Profit	0.15	0	20.1	0	10	10
Selling, General & Admin	34.83	27.53	21.33	12.8	3.18	1.58
Research & Development	135.26	87.27	55.14	33.86	17.38	10.11
Operating Expenses	170.09	114.79	76.47	46.66	20.56	11.69
Operating Income	-169.94	-114.79	-56.37	-46.66	-10.56	-1.69
Interest Expense / Income	0	0	0	0.01	0.01	-0.01
Other Expense / Income	-16.95	-10.11	0.36	-1.13	3.57	0.4
Pretax Income	-152.99	-104.68	-56.73	-45.53	-14.14	-2.09
Income Tax	0	0	2.01	-0.17	0	0.26
Net Income	-152.99	-104.68	-58.74	-45.36	-14.14	-2.35
Shares Outstanding (Basic)	29	25	23	16	2	2
Shares Outstanding (Diluted)	29	25	23	16	2	2
Shares Change	16.66%	8.17%	50.48%	566.41%	7.01%	-
EPS (Basic)	-5.20	-4.15	-2.52	-2.93	-6.08	-1.08
EPS (Diluted)	-5.20	-4.15	-2.52	-2.93	-6.08	-1.08
Free Cash Flow	-126.97	-71.3	-63.17	-37.19	-16.27	6.83
Free Cash Flow Per Share	-4.31	-2.83	-2.71	-2.40	-6.99	3.14
Gross Margin	100.00%	-	100.00%	-	100.00%	100.00%
Operating Margin	-112543.71%	-	-280.46%	-	-105.63%	-16.91%
Profit Margin	-101319.21%	-	-292.26%	-	-141.36%	-23.46%
Free Cash Flow Margin	-84087.42%	-	-314.29%	-	-162.69%	68.25%
EBITDA	-150.63	-103.06	-55.83	-44.92	-13.69	-1.79
EBITDA Margin	-99751.66%	-	-277.77%	-	-136.90%	-17.91%
Depreciation & Amortization	2.37	1.62	0.9	0.61	0.44	0.3
EBIT	-152.99	-104.68	-56.73	-45.53	-14.13	-2.1
EBIT Margin	-101319.21%	-	-282.23%	-	-141.28%	-20.95%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).